Abstract:Idiopathic myelofibrosis (IM) is a clonal haematological malignancy that is thought to originate at the level of the pluripotent haematopoietic stem cell (Baxter et al, 2005). The JAK2V617F mutation has been documented in 50% of patients with IM (Baxter et al, 2005). Pikman et al (2006) and Pardanani et al (2006) have recently defined two gain of function mutations, MPLW515L and MPLW515K (MPLW515L/K), in patients with IM and shown that these mutations play a role in the development of IM. Like JAK2V617F, the MPLW515L/K mutations also lead to activation of JAK-STAT signalling in these IM patients (Pikman et al, 2006). MPLW515L/K mutations are much less common than JAK2V617F but are disease-specific since they solely occur in 5 c. 10% of patients with IM (Lasho et al, 2006; Moliterno et al, 2006; Pardanani et al, 2006; Pikman et al, 2006). MPLW515L/K mutations have been previously detected in DNA from granulocytes of patients with IM (Lasho et al, 2006; Moliterno et al, 2006; Pardanani et al, 2006; Pikman et al, 2006). It is, however, unclear what other haematopoietic cell lineages are involved by these mutations. In the current study, we screened the granulocytes of 38 patients with IM for the MPLW515L/K mutations by DNA sequencing and allele-specific polymerase chain reaction (PCR). All patients met the World Health Organization diagnostic criteria for IM and all human tissue samples were obtained after informed consent was provided. Of the 38 patients, three patients had MPL515 mutations, two with MPLW515L mutation and one with MPLW515K mutation. All patients were heterozygous for the mutations. The frequency of the MPLW515L/K mutations in IM in this study is consistent with other reports (Lasho et al, 2006; Moliterno et al, 2006; Pardanani et al, 2006; Pikman et al, 2006). All three patients were negative for JAK2V617F. To clarify the lineage specificity of the MPLW515L/K mutations, we searched for the presence of MPLW515L/K mutations in different haematopoietic cell lineages in these IM patients. Peripheral blood monocytes (CD14+), B-lymphocytes (CD19+), T-lymphocytes (CD3+) and natural killer (NK) cells (CD16+CD56+) were isolated by flow cytometric cell sorting as previously described (Ishii et al, 2006). The purity of each cell fraction was over 99%. DNA sequencing analysis and allele-specific PCR revealed that each of the three patients was heterozygous for the MPLW515L/K mutations (Fig 1). MPLW515L/K mutations occurred not only in the granulocytes but also in the monocytes, B, T and NK cells of each patient (Fig 1). As DNA sequencing and allele-specific PCR analysis cannot detect MPLW515L/K mutations under 5% and 1% respectively, it appears unlikely that these results were due to contaminating myeloid cells within the highly purified B, T and NK cell populations. Base upon the semi-quantitative methods utilise, the levels of MPLW515L/K mutations appear to be higher in granulocytes and monocytes than B, T and NK cells. These data indicate that the MPLW515L/K mutations are present in both myeloid and lymphoid cells but are predominant in cells belonging to the myeloid lineage. This finding is in contrast to that observed with JAK2V617F myeloproliferative disease where the mutation occurs most commonly in myeloid cells but less frequently in B cells and rarely in T cells (Ishii et al, 2006). Based upon the evidence that the MPLW515L/K mutations are present in both myeloid and lymphoid cells, we conclude that the oncogenic event in IM associated with the MPLW515L/K mutations probably occurs in a progenitor cell common to both myeloid and lymphoid cells, such as the pluripotent haematopoietic stem cell. MPLW515L and MPLW515K mutations in peripheral blood myeloid and lymphoid cells isolated from IM patients detected by direct sequencing analysis and allele-specific PCR. (A) Chromatogram of DNA sequencing illustrating MPLW515L mutation (TGG→TTG) in granulocytes, monocytes, B, T and NK cells (upper panel). The MPLW515L mutation was confirmed by allele specific PCR (lower panel). (B) Chromatogram of DNA sequencing illustrating MPLW515K mutation (TGG→AAG) in granulocytes, monocytes, B, T and NK cells (upper panel). The MPLW515K mutation was confirmed by allele specific PCR (lower panel). The arrows indicate the mutational nucleotides. This work was supported by grants from NCI (1P01CA108671 to RH), the Department of Defense (MP048007 to MX) and (MP048010 to RH), and the Myeloproliferative Disorder Foundation (to MX and RH).

Tyrosine 599 Plays an Essential Role and Cooperates with Tyrosine 604 in MPL W515L-Indiced Myeloproliferative Neoplasms

Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms

Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease

Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases

Adaptor Protein Lnk Negatively Regulates the Mutant MPL, MPLW515L Associated with Myeloproliferative Disorders

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

MPL W515L Mutation in Patients with Myeloproliferative Diseases

A Novel Mutation in MPL (Y252H) Results in Increased Thrombopoietin Sensitivity in Essential Thrombocythemia

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Roles of T875N Somatic Mutation in the Activity, Structural Stability of JAK2 and the Transformation of OCI-AML3 Cells.

A c- MPL Splice Variant up-Regulated in Myeloproliferative Neoplasms Modulates Thrombopoietin Signaling and Induces Cycling of Hematopoietic Stem Cells and Inflammatory Progenitors

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Disruption of R867 and Y613 Interaction Plays Key Roles in JAK2 R867Q Mutation Caused Acute Leukemia.

Inhibition of Akt Signaling Potently Inhibits the Growth of Jak and Mpl-Mutant Cells in the Myeloproliferative Neoplasms in Vitro and in Vivo

Haematopoietic Cell Lineage Distribution of MPLW515L/K Mutations in Patients with Idiopathic Myelofibrosis

Activation Of Jak/Stat Signaling In Megakaryocytes Is Necessary And Sufficient For Myeloproliferation In Vivo

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation in Vivo

The Thrombopoietin/mpl/bcl-Xl Pathway is Essential for Survival and Self-Renewal in Human Preleukemia Induced by AML1-ETO.

C-Mpl-del, an Alternative Splicing Isoform of C-Mpl, Promotes Malignancy and Chemoresistance of AMKL by Regulating AKT/DDIT3 Survival Signaling